Boston Scientific Says Anticipates $25M Negative Impact To 2019 Revenue After The FDA Ordered Manufacturers To Stop Selling Surgical Mesh Products For Transvaginal Repair Of Pelvic Organ Prolapse
Benzinga Newsdesk